Introductory Chapter: Melanoma and Therapeutic Perspectives by Solal, Karine Cohen & Lasfar, Ahmed
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Introductory Chapter: Melanoma 
and Therapeutic Perspectives
Karine Cohen Solal and Ahmed Lasfar
1. Introduction
Malignant melanoma is one of the most aggressive forms of skin cancer, often 
leading to distal metastasis [1, 2]. Melanoma arises often from transformed 
melanocytes as a consequence of durable UV radiation. Unprecedented progress 
in the treatment of advanced melanoma occurred largely through advances 
in understanding how to target selective genetic mutations in patients with 
melanoma, and to unleash exiting anti-tumor immune responses [3–5]. While 
immunotherapy is characterized by induction of durable responses in a limited 
number of patients, targeted therapy has been characterized by high response 
rates [4, 5]. The introduction of targeted therapies has considerably improved 
survival rates in a significant proportion of patients with BRAF-mutant melano-
mas [6, 7]. However, drug resistance significantly weakens the efficacy of almost 
all current anticancer therapies [8, 9]. This resistance to therapy is generally 
driven by intrinsic or acquired tumor mechanisms [10]. Understand underlying 
mechanisms of resistance is crucial in elaborating novel therapeutic strategies 
(Figure 1).
Figure 1. 
Current melanoma therapies. Several therapies are currently used in clinic for the treatment of melanoma 
patients. Current therapies are based on targeted therapy, immune therapy and combination therapy, consisting 




2. Therapeutic resistance to targeted therapy
Emergence of drug resistance, usually within several months considerably 
limited expected survival benefits [8, 9]. The V600E activating mutation of BRAF 
(MAPK pathway effector) induces constitutive activation of the kinase in 45–60% 
of cutaneous melanomas, and inhibitors of BRAF, MEK or both have revolutionized 
the treatment of patients with BRAF-mutated melanoma [10, 11]. Some mecha-
nisms of drug resistance have been being identified and strategies to circumvent 
therapy failure are being investigated in preclinical models and clinical studies [12].
Accumulating evidence demonstrated that in the context of acquired resistance, 
tumor cells will develop mechanisms that not only promote resistance to BRAF 
V600E targeted therapy but also increase invasiveness favorable to further dissemi-
nation and metastasis [10, 13, 14]. The molecular effectors involved in resistance to 
BRAF V600E targeted therapy are simultaneously playing key roles in melanoma 
cell motility and invasiveness [8, 10]. Numerous studies documented that resistance 
is often coupled to the development of an aggressive tumor phenotype, character-
ized by an active epithelial-to mesenchymal (EMT)-like process, increased motility 
and invasion [15, 16]. As a well-documented example, transcription factors and 
coactivators play an active role in resistance to BRAF V600E targeted therapy, 
through a large variety of mechanisms [17]. In addition to promoting adaptive or 
acquired resistance, the expression levels of some of these transcription factors 
promotes a state of intrinsic resistance in the context of melanoma cells harboring 
BRAF V600E mutations [18–20].
General mechanisms of BRAF inhibitor resistance involve up or down regula-
tion of transcription factors, phosphorylation of transcription factors, as well as 
modulation of their subcellular localization [17–20]. These alterations are associated 
with diverse oncogenic mechanisms, such as induced expression of ERK kinases 
or stabilization of their phosphorylation, an increase and/or activation of specific 
receptor tyrosine kinases, such as EGFR, IGF-1R, AXL PDGFRβ, ERBB3, or the 
activation of the TGF-β signaling pathway [17, 19]. Moreover, G-protein-coupled 
receptors are being involved as a new protein class whose dysregulation underlies a 
cascade of transcriptional events resulting in resistance to BRAF inhibition. These 
studies altogether strongly suggest that the resistance mechanisms reestablish 
activation of the MAPK pathway, on which melanoma cells are highly dependent for 
survival, proliferation, aggressiveness and pro-metastatic behavior [17, 21]. In addi-
tion, reactivation of additional pathways, such as the PI3K/AKT pathway or GPCR-
mediated cAMP/PKA/CREB pathway further operate for rewiring melanoma cells 
towards more aggressive characteristics in conjunction with drug resistance [21].
Simultaneous rewiring of oncogenic signaling pathways, phenotypic plasticity 
favoring pro-invasive behavior, actin remodeling and cytoskeletal tension, and 
bidirectional interplay between tumor cells and melanoma microenvironment, 
represent remaining challenges, for overcoming resistance to BRAF V600E 
inhibitors [22].
Other mechanisms of drug resistance have been identified in both melanoma 
patients and BRAF-animal models. Recently, it has been reported that BRAF 
interacts with GRP78 and removes its inhibitory impact on the three major ER stress 
sensors of UPR, PERK, IRE1α, and ATF6. Disconnection of GRP78 from these ER 
stress sensors stimulates UPR that consequently activates cytoprotective autophagy. 
Thus, inhibition of BRAF-induced ER stress-mediated autophagy can possibly 
resensitize BRAF mutant melanoma tumors to apoptosis [23].
Melanomas frequently display hyperactivity of nitric oxide synthase (NOS) and 
NADPH oxidase (NOX), which, respectively, produce nitric oxide (NO·) and super-
oxide (O2·−). The NO· and O2− react instantaneously with each other to produce 
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peroxynitrite (ONOO−) which is the driver force of melanin chemiexcitation. 
Melanocytes, the skin cells, specialized in synthesizing melanin, a shield against 
sunlight’s ultraviolet (UV) radiation. However, melanin chemiexcitation paradoxi-
cally demonstrates the melanomagenic properties of melanin. In a loop, the NOS 
activity regulates melanin synthesis, and melanin is utilized by the chemiexcitation 
pathway to generate carcinogenic melanin-carbonyls in an excited triplet state. 
These carbonyl compounds induce UV-specific DNA damage without UV [24].
It has been also reported that melanoma cells gain drug resistance to 
Temozolomide through a complex inflammatory mechanism, involving 
Inflammasome Sensor NLRP1 [25].
There is emergent indication that altered expression levels of microRNAs 
(miRNA)s induce drug-resistance in melanoma cells and that restoring adequate 
expression of miRNAs is critical in the re-establishment of therapeutic  
sensitivity [26].
3. Immunotherapy resistance
On the other hand, since the first immune checkpoint inhibitor (ICI) approval 
of an anti-CTL-A monoclonal antibody (mAb) in 2011 for unresectable/metastatic 
melanoma, the class continued to evolve, resulting in an always-changing standard 
of care for patients. Unfortunately, innate and acquired resistance to ICIs prevent 
a substantial number of patients with advanced melanoma to benefit from these 
clinical breakthroughs [27]. As the mechanisms responsible for both innate and 
acquired resistance to ICIs are further elucidated, therapeutic strategies to over-
come these resistances are being clinically evaluated and will undoubtedly provide 
superior therapeutic efficacy [28].
As an example, clinical trials are currently evaluating inhibitors of myeloid-
derived suppressors cells, which have emerged as important components in 
resistance to cancer immunotherapy [29, 30]. In addition, intra-tumor injection 
of interleukin-12, GMCSF, and Toll-like receptors (TLR9) agonists, among other 
agents are currently evaluated in patients with melanoma refractory to anti-PD1 
blockade [31, 32]. Another approach clinically tested in patients with BRAFV600E 
is the triple combination of an approved anti-PD-L1 monoclonal antibody and an 
approved combination of BRAF inhibitor/MEK inhibitor; this triplet regimen is 
based on the rationale that BRAF inhibition increases the penetration of T cells 
into the tumors, a major factor in the ability to respond to ICIs [33]. Altogether, the 
different approaches aim at transforming a cold tumor, characterized by a lack or 
paucity of tumor T cell infiltration, into a hot, inflamed tumor.
4. Alternative therapeutic strategies
Other alternative approaches have been elaborated in the treatment of meta-
static melanoma such as Photodynamic therapy (PDT), which relies on a light-
activated compound to produce death-inducing amounts of reactive oxygen species 
(ROS) [34].
Histone Deacetylase Inhibitors have been also developed to overcome resistance 
to targeted and immunotherapy in Metastatic Melanoma [35].
Nanotechnology, based therapy or neoadjuvant therapy represent an active 
area of investigation as demonstrated by several clinical trials [36]. These novel 
strategies may offer a multitude of benefits which could improve the survival 
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immunotherapies and vaccines are expected to overcome drug resistance, offer-
ing survival benefits to a greater population of patients with advanced melanoma, 
while maintaining a satisfying quality of life.
5. Conclusion
The future of patients with unresectable and advanced melanoma is look-
ing brighter than a decade ago. Besides immunotherapy revolution, promising 
approaches are emerging. Currently combination therapy, based on targeted 
therapy and immune checkpoint inhibitors is commonly recommended for 
increasing treatment efficacy. However, many challenges remain, regarding the 
mechanisms of tumorigenesis, the impact of tumor microenvironment on the 
immunogenicity of melanoma.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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